You Position: Home > Paper
Targeted therapy of colorectal cancer
( views:324, downloads:56 )
- Author:
- No author available
- Journal Title:
- CANCER RESEARCH AND CLINIC
- Issue:
- 2
- DOI:
- 10.3760/cma.j.issn.1006-9801.2006.02.001
- Key Word:
- 贝伐单抗;西妥昔单抗;大肠癌
Abstract： 阐述了贝伐单抗(BV)与西妥昔单抗(C225)治疗晚期或转移性大肠癌(CRC)的作用.分子靶向药物BV与C225能特异性阻断血管内皮生长因子(VEGF)和表皮生长因子受体(EGFR)的生物效应,临床应用治疗CRC有效且耐受良好,它与细胞毒药物不同,主要是抑制肿瘤生长,而不是缩小,与化疗联合应用可望增强疗效,延长生存期,改善生活质量.
- [1]Naureen, Starling,David, Cunningham.Cetuximab in previously treated colorectal cancer.[J].2005,5.
- [2]Shia J,Pan D,Fridman D,etc.Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.[J].2005,23(9).
- [3]Hainsworth JD,Hambleton J,Hurwitz HI,etc.Bevacizumab in combination with Fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.[J].2005,23(15).
- [4]主编韩锐, 孙燕.新世纪癌的化学预防与药物治疗[M].2005.
- [5]Berlin JD,Lockhart C.The epidermal growth factor receptor as a target for colorectal cancer therapy.[J].2005,32(1).
- [6]Kohne CH,Folprecht G.The role of new agents in the treatment of colorectal cancer.[J].2004,66(1).
- [7]Hecht JR,Patel T,Perrou B,etc.Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.[J].2005,23(16).
- [8]Venook A.Critical evaluation of current treatments in metastatic colorectal cancer.[J].2005,10(4).
- [9]Tan BR,McLeod HL.Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.[J].2005,32(1).
- [10]Hainsworth JD,Novotny W,Cartwright T,etc.Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.[J].2005,91(3).
- [11]Collins TS,Hurwitz HI.Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.[J].2005,32(1).
- [12]Choti, M. A..Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer[J].2004,30(8).
- [13]Bleiberg H,Cunningham D,Van Cutsem E,etc.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.[J].2004,351(4).
- [14]Gordon M,Vallbohmer D,Lenz HJ,etc.Molecular determinants of cetuximab efficacy.[J].2005,23(15).
- [15]Naureen, Starling,David, Cunningham.Second-line therapy for advanced colorectal carcinoma.[J].2005,7(3).